Last week, OncoSil Medical was pleased to release a new investor presentation - available here - summarising our mission, market opportunity we are addressing, as well as recent clinical study results which show excellent local disease control and safety using our device.
Despite the 130,000 cases of pancreatic cancer diagnosed in the EU and US each year alone, there has been an absence of true innovation in the treatment of non-resectable pancreatic cancer patients. Given this situation, there is a significant opportunity for OncoSil™ to become the standard of care in combination with Chemotherapy following regulatory approval.
This week, * author Andrew Ramadge published an article on OncoSil Medical - available here – covering the company’s progress to date, differentiated approach to peer Sirtex, and commercial pathway ahead.
We will be presenting further study data at two major upcoming international congresses:
The 12th World Congress of the Federation of Nuclear Medicine and Biology in Melbourne during 20-24 April
The Digestive Disease Weekly (DDW) Conference in Washington during 2-5 June
It is an exciting time for OncoSil Medical, and I look forward to updating you on our progress moving forward.
Thank you for your continued support.
Sincerely,
Daniel Kenny
OSL Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)